Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisAnalysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCGefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusQuantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung CancerDetection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsThe Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer.EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysisComparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusComparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinibDigital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1.Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialNoninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysisEmerging molecular biomarkers--blood-based strategies to detect and monitor cancer.
P2860
Q26741318-96A22453-0B36-404A-A492-1897AB829FE0Q26769734-DB129742-29BF-4A68-9307-C06EB8F0149BQ26775376-2E82003F-123D-4CBA-8BD9-73D0E6AFAB5CQ26801357-BE063153-4FD7-4DDE-9B33-70FBCAFB2FA8Q28087366-6EBF2964-F121-4171-8650-BBB41B0CB4F0Q33598423-691389BB-B089-4696-BDA1-402C900306D5Q33735738-2F0D8E91-ABD8-48D4-8CAF-C4FB83E60D6FQ33779727-289336DF-7F12-41E0-BB82-F36C808FCD22Q34002791-BBE74C13-1B1A-447C-96EF-ED75329A2418Q34092157-83F5B0CA-01C8-4DEA-AA5F-F3A532DE8A15Q34311186-05BAA4EC-6B0B-4859-8D7D-4DB1806D6CA8Q34473831-30B20694-8C7E-461B-9679-7026D21C08D8Q34535332-F5BB9B41-4E80-493B-8720-816DE004BD80Q34634536-B12B42C3-DE0C-4FB1-BBF6-07F19B13E947Q35587176-C7A97DF0-282A-4989-94A1-932CB9EEBD64Q35654703-220ECDF5-C0CF-4753-8897-61402B0BE8D3Q35764712-2FD10D28-ADBE-40CE-9364-0914C6F73120Q36095650-E8948240-47FA-489B-AA13-36974D91FF8BQ36278010-245D808E-D7CD-49A7-A482-7398C3EBE26DQ36282366-F78A6B75-452C-4C48-82EC-EEA2E1C3815EQ36375343-1B834D27-A05A-4042-A73A-945DC21237F9Q36474664-4C001906-6C06-4A17-8568-098D70D6A5C2Q36544438-5FF57F1E-7D02-47E5-A7CB-E9FC31844281Q36844366-7E7F389C-49DB-4047-8AD1-941270123829Q36916399-866D4AF3-553E-40D3-A4BD-A779DABA6417Q37114899-80CE487B-0788-4FD1-AF2B-5D020E0A1FCFQ37217593-BDE8E15C-83AC-4E54-BE49-CB12C02191BDQ37251422-C99F5E6F-DEFE-48A8-9526-C6B704AF66BBQ37307603-2B69F54B-451E-4ECE-9433-BCC57DEAEA2AQ37334996-4236D40A-51F7-4110-8FAC-2DB5692DADCBQ37499417-0032BEDB-FDE8-48DC-94BA-554130EB2DB0Q37536958-E29D573C-F1A1-4C13-B37C-AF5A37BC920FQ37579644-04E36B83-94A0-4D51-AD3B-887D6ACCD265Q37592893-58EC2DA6-CD26-407F-8931-EB79ED77E0A0Q37659062-3BF77851-1C47-4D63-9F0B-F04B3F2D38ABQ37690677-7B80275E-3002-448F-ACA0-A5AF9D3383E9Q37701499-886F588E-A39A-4C7F-8C76-9E19CC48D40FQ37726138-F8D323B3-D14C-4BAF-92E0-BA2A12323F74Q37743832-6AE8C724-5D3A-4035-AFF1-CD1A2F93C9A6Q37848663-0FE8B246-1FE7-4EB6-AEE4-EE9D4B7CD236
P2860
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@ast
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@en
type
label
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@ast
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@en
prefLabel
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@ast
Evaluation of epidermal growth ...... esponse to gefitinib (IRESSA).
@en
P2093
P2860
P356
P1476
Evaluation of epidermal growth ...... response to gefitinib (IRESSA)
@en
P2093
K Kasahara
K Miyamoto
M Fujimura
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603949
P407
P577
2007-09-01T00:00:00Z